• Employees: 38,000

• Business activities in more than 100 countries

• Sales in 2007: EUR 10.267 billion

• Headquarter: Berlin (Germany)

The 2006 acquisition of Schering was the largest purchase in Bayer’s history. The takeover led to the formation of Bayer Schering Pharma, a powerful, leading company that ranks among the top ten pharmaceutical specialists in the world and holds a strong position in Biologicals.

Schering brought a comprehensive range of products that ideally complement Bayer's portfolio to the new company. Bayer Schering Pharma is concentrating on four strategic business units: Diagnostic Imaging, General Medicine, Specialty Medicine, and Women’s Healthcare.

The merger has produced a strong company with successful, well-established brands.

Its highest-selling products include:

• Yasmin® (hormonal contraceptive)
• Betaferon®/Betaseron® (multiple sclerosis)  
• Kogenate® (hemophilia)
• Adalat® (hypertension)
• Avalox®/Avelox® (respiratory tract infections) 
• Ciprobay®/Cipro® (infectious diseases, especially of the urinary tract)
• Mirena® (hormonal contraceptive)
• Levitra® (erectile dysfunction)
• Magnevist® (contrast medium for magnetic resonance imaging  
• Glucobay® (diabetes) 

• Link: Health advice on Bayer Schering Pharma topics
• Link: Bayer Schering Pharma research activities
• External Link: Internet portal of the Bayer Schering Pharma